GlassScriptPhysician profile
Amy G King
NPI 1760788749
$1,715.23
in general payments reported to CMS, 2019-2025
16 companies · $200 in 2025
The $200 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $502 · 2022: $422 · 2023: $280 · 2024: $311 · 2025: $200.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $791.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $791.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exeltis, USA INC. | $293.58 | 2021-2024 | Slynd |
| Abbvie INC. | $226.34 | 2021-2024 | |
| Novo Nordisk INC | $223.49 | 2021-2025 | Wegovy |
| Mayne Pharma Commercial LLC | $173.52 | 2022-2025 | |
| Therapeuticsmd, INC. | $157.75 | 2021-2022 | |
| Millicent US INC | $110.28 | 2023-2025 | Femlyv, Intrarosa |
| Evofem Biosciences, INC. | $106.98 | 2021-2024 | Phexxi |
| Axonics, INC. | $79.50 | 2023 | Axonics |
| Biogen, INC. | $78.95 | 2024-2025 | Zurzuvae |
| Organon LLC | $75.77 | 2024 | |
| Hologic Sales and Service, LLC | $67.99 | 2022-2023 | Aptima, Novasure |
| Avion Pharmaceuticals | $52.32 | 2021-2022 | |
| Scynexis, INC. | $24.71 | 2022 | |
| Mylan Pharmaceuticals INC. | $17.19 | 2021 | |
| Radius Health, INC. | $14.63 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $12.23 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy King listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.